KOE · 028300.KQ
HLB Co., Ltd.
₩39,450-₩250 (-0.63%)
HLB Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.99% below the high.
Loading market information…
KOE · 067630.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 02:52 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
HLB Life Science Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow HLB Life Science Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HLB Life Science Co., Ltd., founded in 1998 and situated in Hwaseong, South Korea, operates a multifaceted business, having previously been known as Energy Solutions Co., Ltd. until its name change in December 2015. The company's core focus involves the global wholesale and distribution of pharmaceutical products, alongside significant investment in developing innovative medical treatments. Key among these are several drug candidates: Rivoceranib, a small-molecule tyrosine kinase inhibitor, is under development for a broad spectrum of cancers, including gastric, colorectal, hepatocellular, non-small cell lung, esophageal, thyroid, mesothelioma, and neuroendocrine tumors. Seclidemstat, an oral epigenetic small molecule, aims to restore normal gene expression and suppress tumor proliferation in various solid tumors like those found in the lung, breast, and prostate. Tegavivint, which functions as an inhibitor of the Wnt/β-catenin pathway, is being advanced for conditions such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of other solid tumor types. Beyond pharmaceuticals, HLB Life Science is also pioneering advanced medical technologies, including: LifeLiver, an extracorporeal bioartificial liver system. HepaStem, a therapeutic approach leveraging heterologous human adult liver-derived progenitor cells. HLBLS-200, a biocompatible polysaccharide-based powder designed to achieve adhesive hemostasis upon contact with blood. Additionally, the company maintains a robust presence in the energy sector. Its activities span waste heat recovery, cogeneration power generation, and the installation of facilities. It actively participates in various energy ventures, including solar power (photovoltaic generation), bioenergy, geothermal energy, waste-to-energy conversion, wind power, and fuel cell technologies. Furthermore, HLB Life Science undertakes projects focused on enhancing energy efficiency and implementing improvements to heating systems.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩39,450-₩250 (-0.63%)
HLB Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.99% below the high.
₩38,400-₩2,600 (-6.34%)
ABL Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.09% below the high.
₩105,100-₩10,100 (-8.77%)
Voronoi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.01% below the high.
₩39,500-₩2,200 (-5.28%)
D&D Pharmatech’s quoted price sits in the lower half of its reported 52-week range, 66.12% below the high.
₩35,600-₩900 (-2.47%)
Oscotec Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.06% below the high.
₩12,010-₩610 (-4.83%)
Onconic Therapeutics’s quoted price sits in the lower half of its reported 52-week range, 58.44% below the high.
₩9,300-₩210 (-2.21%)
HLB Pharmaceutical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 58.2% below the high.
₩2,475-₩85 (-3.32%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.5% below the high.
